Proteolytics Announces In-Vivo Study to Treat Chronic Wounds with OPAL-A Pawpaw Extract

Perth, Western Australia, 02 August 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced a proposed comparative in-vivo study

Proteolytics Announces First Data from Treatment of Skin Irritation with OPAL-A Pawpaw Extract

Perth, Western Australia, 22 July 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced that an evaluation of the

Proteolytics Announces First Data from Treatment of Horses with OPAL-A

Perth, Western Australia, 12 July 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced that initial results from an

Proteolytics Collaborates with University of Florida to Advance ProteoActiv™ Technology

Perth, Western Australia, 05 July 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced that it is collaborating with

Formation of MSAC

Proteolytics Forms Medical & Scientific Advisory Committee. Three members recognised as industry experts in wound care. Click here to view announcement

WA delegation at US BIO

Proteolytics to Join WA Delegation at BIO International Convention. Click here to view announcement

Proteolytics incorporated

Proteolytics Spun-off from Phoenix Eagle Company. Click here to view announcement